New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:16 EDTGILDGilead data negative, says Wells Fargo
Wells Fargo believes that data on Gilead's P13K+Syk treatment indicates that it is toxic. However, the firm remains upbeat on the company's Idelalisib drug and keeps an Outperform rating on the shares.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 3, 2016
08:03 EDTGILDGilead initiated with a Buy at Standpoint Research
Target $110.
07:39 EDTGILDGilead's bottom line makes it look like a value stock, says Baird
Subscribe for More Information
February 2, 2016
19:22 EDTGILDOn The Fly: After Hours Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 16.5%... Wabash National (WNC), up 9.7%... Oclaro (OCLR), up 6.8%... Myriad Genetics (MYGN), up 8%... Ultimate Software Group (ULTI), up 6.2%... Natural Health (NHTC), up 6.2%... Edwards Lifesciences (EW), up 6.2%... Viavi Solutions (VIAV), up 2.4%... Gilead Sciences (GILD), up just under 1%. DOWN AFTER EARNINGS: Match Group (MTCH), down 7.3%... Yahoo (YHOO), down 1.2%... Chipotle (CMG), down 7.1%. ALSO LOWER: Barnes & Noble (BKS), down 2.4% after General Growth (GGP) CEO Sandeep Mathrani announced that Amazon (AMZN) is going to open 300-400 brick-and-mortar bookstores.
18:36 EDTGILDGilead price target lowered to $114 from $134 at Piper Jaffray
Subscribe for More Information
16:07 EDTGILDGilead raises quarterly dividend 10%, announces additional $12B share buyback
Subscribe for More Information
16:05 EDTGILDGilead raises quarterly dividend 10%, announces additional $12B share buyback
16:04 EDTGILDGilead sees FY16 adjusted product gross margin 88%-90%
Sees FY16 Diluted EPS Impact Related to Acquisition, Stock-Based Compensation and Other $1.10 - $1.16.
16:04 EDTGILDGilead sees FY16 net product sales $30B-$31B, consensus $31.68B
16:03 EDTGILDGilead reports Q4 other product sales $523M
Subscribe for More Information
16:02 EDTGILDGilead reports Q4 antiviral product sales increased to $7.9B
Antiviral product sales, which include products in our HIV and liver diseases areas, were $7.9B for the fourth quarter of 2015 compared to $6.7B for the fourth quarter of 2014 primarily as a result of the launch of our HCV products in Japan and continued launches of our HCV products across Europe, partially offset by lower sales of HCV products in the U.S. For 2015, antiviral product sales were $30.2B compared to $22.8B in 2014 primarily due to sales of Harvoni, partially offset by a decrease in sales of Sovaldi.
16:01 EDTGILDGilead reports Q4 total product sales $8.4B
Total product sales for the fourth quarter of 2015 were $8.4B compared to $7.2B for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8B compared to $5.5B in the fourth quarter of 2014. In Europe, product sales were $1.7B compared to $1.4B in the fourth quarter of 2014. Sales in other international locations increased to $1.9B compared to $373M in the fourth quarter of 2014, primarily due to sales of Sovaldi(R) (sofosbuvir 400 mg) and Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) in Japan.
16:00 EDTGILDGilead reports Q4 adjusted EPS $3.32, consensus $3.00
Subscribe for More Information
14:32 EDTGILDNotable companies reporting after market close
Subscribe for More Information
12:33 EDTGILDGilead February weekly 83 straddle priced for 6% movement into Q4
11:52 EDTGILDGilead technical notes before earnings news
There is an active bearish head and shoulders pattern on the daily chart that became active when price broke below $93. Downside potential for the pattern, if it remains active and completes, is to the $65 to $62.50 area over time. If the news is bearish, the pattern is likely to continue to develop. If the news is a bullish surprise, it is possible that the pattern will become inactive if price can rise above $93. To void the pattern entirely would take a move above $110.
09:46 EDTGILDIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
February 1, 2016
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open: BAC AAPL FB AMZN TWTR MGM MCD NFLX GILD INTC TSLA AA BABA C
09:23 EDTGILDGilead volatility elevated into Q4 and outlook
Gilead February weekly call option implied volatility is at 62, February is at 44, March is at 38; compared to its 52-week range of 22 to 49, suggesting large near term price movement into the expected release of Q4 results on February 2.
09:05 EDTGILDGilead says EMA validates Type II variation application for Truvada
Subscribe for More Information
05:17 EDTGILDStocks with implied volatility movement; GILD PBR
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use